Progress of classification and prognosis of diffuse large B-cell lymphoma

VernacularTitle:弥漫大B细胞淋巴瘤分型及预后研究进展
Author: Yuxi GONG ¹ ; Boya ZHAI ; Yefan YANG ; Zhihong ZHANG
Author Information

1. 南京医科大学第一附属医院病理科，南京　210029
Keywords: Lymphoma, large B-cell, diffuse; Immunotherapy; Genome; Molecular typing; Prognosis
From: Journal of Leukemia & Lymphoma 2021;30(9):565-568
CountryChina
Language:Chinese
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, with high clinical and biological heterogeneity. Only 60% of patients can benefit from standard immunochemotherapy. Looking for new clinical parameters and biomarkers to better classify and stratify the prognosis of DLBCL patients has been the focused area in recent years. This article reviews the classifications and their prognostic significances of DLBCL by analyzing the related studies of genome and transcriptome.